Given there are serious limitations to pharmaceutical cannabinoid medications, it’s clear that the problem lies in the insurance system that has yet to evolve alongside patients’ needs and medical science. There is a clear disconnect when insurance companies can cover synthetic cannabinoid drugs but can’t acknowledge the medicinal value of whole cannabis compounds. Then again, the issue circles back to the federal government.
Germany has received nearly 900 applications for cannabis cultivation associations, but only just over half…
A Senate stopgap funding bill would delay the federal prohibition on most hemp-derived THC products…
He smokes in boardrooms, but he’s still on that underground frequency. This content originally appeared…
Fox News opinion ran a piece recently from Scott Chipman, vice president of Americans Against…
For our 50th anniversary, we handed the plant to the artists making its most striking…
Corporate valuation increased in 21 of the 38 states studied following medical marijuana legalization. Gross…